But there’s a big problem — DeepSeek does not appear to have conducted any predeployment safety testing. There is no mention ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

“Bill Gates was bitching about us changing JS all the time,” Eich later recalled of the fall of 1996. Microsoft created its ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and ...

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

Trevor Lawrence has played plenty of meaningful games in December. And not just at Clemson. The Jaguars quarterback was part ...

Luka Doncic had 33 points and 11 rebounds and LeBron James scored 17 points in his first road game of the season as the Los ...